Comparison of potential biological markers cathepsin B, cathepsin L, stefin A and stefin B with urokinase and plasminogen activator inhibitor-1 and clinicopathological data of breast carcinoma patients

被引:48
|
作者
Levicar, N
Kos, J
Blejec, A
Golouh, R
Vrhovec, I
Frkovic-Grazio, S
Lah, TT
机构
[1] Natl Inst BIol, Dept Genet Toxicol & Canc Biol, Ljubljana 1000, Slovenia
[2] Jozef Stefan Inst, Dept Biochem & Mol Biol, Ljubljana 61111, Slovenia
[3] KRKA DD, Novo Mesto, Slovenia
[4] Inst Oncol, Dept Pathol, Ljubljana, Slovenia
[5] Inst Oncol, Dept Clin Biochem, Ljubljana, Slovenia
来源
CANCER DETECTION AND PREVENTION | 2002年 / 26卷 / 01期
关键词
cathepsin B; cathepsin L; stefin A; stefin B; urokinase (u-PA); PAI-1; breast cancer;
D O I
10.1016/S0361-090X(02)00015-6
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Cysteine, serine and metalloproteinases and their respective inhibitors are involved in tumor cell invasion and may have prognostic value for the outcome of malignant disease. The aim of the study was to compare the expression of new potential biological tumor markers, the lysosomal cysteine proteinases and their endogenous inhibitors, with that of the serine proteinases and their inhibitors in breast cancinoma and to relate their levels to the clinicopathological factors of the disease. Enzyme-linked immunosorbent assays (ELISAs) were used to measure cysteine cathepsin B (CatB) and cathepsin L (CatL) and their inhibitors, stefin A (StA) and stefin B (StB), together with urokinase (u-PA) and plasminogen activator inhibitor-1 (PAI-1), in 150 cytosols of primary invasive breast carcinoma. A good correlation was found between the levels of the two cysteine proteinases but only a moderate one between those of the cysteine and serine proteinases. u-PA and PAI-1 levels correlated positively with histological grade and negatively with estrogen receptor (ER) status. PAI-1 correlated with most clinicopathological factors that indicate the progression of the disease, while cathepsins and stefins were independent of these factors. In the total group of patients, high u-PA and PAI-1 and low SIB levels correlated significantly with shorter disease-free survival (DFS), while CatB, CatL and StA did not. In lymph node negative patients, high CatB and CatL were also associated with shorter DFS, while u-PA remained the most significant of all these biological markers. In conclusion, this retrospective study showed u-PA to be of better prognostic relevance than the cysteine proteinases, though CatB and CatL were relevant for prognosis in lymph node negative breast cancer patients. (C) 2002 International Society for Preventive Oncology. Published by Elsevier Science Ltd. All rights reserved.
引用
收藏
页码:42 / 49
页数:8
相关论文
共 38 条
  • [21] Cathepsin-D, urokinase plasminogen activator and type-1 plasminogen activator inhibitor in early breast cancer: an immunohistochemical study of prognostic value and relations to tenascin-C and other factors
    T Jahkola
    T Toivonen
    K von Smitten
    I Virtanen
    V-M Wasenius
    C Blomqvist
    [J]. British Journal of Cancer, 1999, 80 : 167 - 174
  • [22] Cathepsin-D, urokinase plasminogen activator and type-1 plasminogen activator inhibitor in early breast cancer: an immunohistochemical study of prognostic value and relations to tenascin-C and other factors
    Jahkola, T
    Toivonen, T
    von Smitten, K
    Virtanen, I
    Wasenius, VM
    Blomqvist, C
    [J]. BRITISH JOURNAL OF CANCER, 1999, 80 (1-2) : 167 - 174
  • [23] Clinical significance of the serine protease uPA (urokinase) and its inhibitor PAI-1 as well as the cysteine proteases cathepsin B and L in breast cancer
    Schmitt, M
    Thomssen, C
    Janicke, F
    Hofler, H
    Ulm, K
    Magdolen, V
    Reuning, U
    Wilhelm, O
    Graeff, H
    [J]. BREAST CANCER - ADVANCES IN BIOLOGY AND THERAPEUTICS, 1996, : 191 - 200
  • [24] PROGNOSTIC-SIGNIFICANCE OF CELLS POSITIVE FOR CATHEPSIN-D AND UPA (UROKINASE PLASMINOGEN-ACTIVATOR) IN BONE-MARROW OF PATIENTS WITH PRIMARY BREAST-CARCINOMA
    DIEL, IJ
    KAUFMANN, M
    GOERNER, R
    COSTA, SD
    QUATY, S
    KRAMER, M
    BASTERT, G
    [J]. ARCHIVES OF GYNECOLOGY AND OBSTETRICS, 1993, 254 (1-4) : 858 - 860
  • [25] Prognostic impact of proteolytic factors (Urokinase-Type plasminogen activator, plasminogen activator inhibitor 1, and cathepsins B, D, and L) in primary breast cancer reflects effects of adjuvant systemic therapy
    Harbeck, N
    Alt, U
    Berger, U
    Krüger, A
    Thomssen, C
    Jänicke, F
    Höfler, H
    Kates, RE
    Schmitt, M
    [J]. CLINICAL CANCER RESEARCH, 2001, 7 (09) : 2757 - 2764
  • [26] Circulating miR-10b, soluble urokinase-type plasminogen activator receptor, and plasminogen activator inhibitor-1 as predictors of non-small cell lung cancer progression and treatment response
    Setiawan, Lyana
    Setiabudy, Rahajuningsih
    Kresno, Siti Boedina
    Sutandyo, Noorwati
    Syahruddin, Elisna
    Jovianti, Frederica
    Nadliroh, Siti
    Mubarika, Sofia
    Setiabudy, Rianto
    Siregar, Nurjati C.
    [J]. CANCER BIOMARKERS, 2024, 39 (02) : 137 - 153
  • [27] MicroRNA-30b protects myocardial cell function in patients with acute myocardial ischemia by targeting plasminogen activator inhibitor-1
    Li, Bin
    Hu, Jie
    Chen, Xingpeng
    [J]. EXPERIMENTAL AND THERAPEUTIC MEDICINE, 2018, 15 (06) : 5125 - 5132
  • [28] Prognostic impact of tissue concentration of urokinase (uPA), its receptor (uPAR), and plasminogen activator inhibitor-1 (PAI-1) on the survival of patients with breast cancer: A prospective study
    Costantini, V
    Cazzato, AO
    Pasqualini, ME
    DeMonte, P
    Vienna, L
    Mariotti, M
    Deveglia, R
    Tonato, M
    Nenci, GG
    [J]. THROMBOSIS RESEARCH, 1998, 91 (03) : S138 - S139
  • [29] Low cathepsin D and low plasminogen activator type 1 inhibitor in tumor cytosols defines a group of node negative breast cancer patients with low risk of recurrence
    Kute, TE
    Grondahl-Hansen, J
    Shao, SM
    Long, R
    Russell, G
    Brünner, N
    [J]. BREAST CANCER RESEARCH AND TREATMENT, 1998, 47 (01) : 9 - 16
  • [30] Low cathepsin D and low plasminogen activator type 1 inhibitor in tumor cytosols defines a group of node negative breast cancer patients with low risk of recurrence
    Timothy Edward Kute
    Jan Grøndahl-Hansen
    Si-Ming Shao
    Rena Long
    Greg Russell
    Nils Brünner
    [J]. Breast Cancer Research and Treatment, 1998, 47 : 9 - 16